Stockholm, Sweden

Magnus Doverskog

USPTO Granted Patents = 5 

 

 

Average Co-Inventor Count = 4.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2017-2021

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: **Innovator Spotlight: Magnus Doverskog from Stockholm**

Introduction

Magnus Doverskog is a prominent inventor based in Stockholm, Sweden, known for his significant contributions to pharmaceutical formulations. With a total of five patents to his name, Doverskog has made strides in areas that are crucial for medical advancements.

Latest Patents

His latest inventions include a novel pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime. This innovative formulation comprises 0.1-10% by weight of the active compound along with a vehicle that contains 45-100% of a monoester and optional diester and triester components. The formulation is particularly noteworthy for its potential use in treating medical conditions such as hypersomnia and hepatic encephalopathy.

Career Highlights

Doverskog currently works with Umecrine Cognition AB, a company recognized for its focus on innovative pharmaceuticals. His work has contributed to the development of critical treatments, making him a valued member of the research community in the pharmaceutical sector.

Collaborations

Throughout his career, Doverskog has collaborated with notable coworkers including Torbjörn Bäckström and Maja Johansson. These collaborations have facilitated rich exchanges of ideas and furthered the impact of their collective innovations in the field of pharmacology.

Conclusion

Magnus Doverskog stands out as an inventor dedicated to advancing pharmaceutical science. His innovative formulations and collaborative efforts reflect a commitment to improving medical treatments, underscoring the essential role of inventors in driving progress in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…